Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Revenue (2019 - 2025)

Eton Pharmaceuticals' Revenue history spans 7 years, with the latest figure at $21.3 million for Q4 2025.

  • On a quarterly basis, Revenue rose 82.72% to $21.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.5 million, a 65.22% increase, with the full-year FY2025 number at $80.0 million, up 104.94% from a year prior.
  • Revenue hit $21.3 million in Q4 2025 for Eton Pharmaceuticals, down from $22.5 million in the prior quarter.
  • Over the last five years, Revenue for ETON hit a ceiling of $29.8 million in Q4 2023 and a floor of $775000.0 in Q3 2021.
  • Historically, Revenue has averaged $9.9 million across 5 years, with a median of $8.2 million in 2022.
  • Biggest five-year swings in Revenue: soared 203200.0% in 2021 and later crashed 81.71% in 2022.
  • Tracing ETON's Revenue over 5 years: stood at $6.1 million in 2021, then surged by 39.47% to $8.5 million in 2022, then skyrocketed by 250.69% to $29.8 million in 2023, then tumbled by 60.92% to $11.6 million in 2024, then soared by 82.72% to $21.3 million in 2025.
  • Business Quant data shows Revenue for ETON at $21.3 million in Q4 2025, $22.5 million in Q3 2025, and $18.9 million in Q2 2025.